The carbonic anhydrase enzymes as new targets for the management of neglected tropical diseases

Gioele Renzi,Federico Ladu,Fabrizio Carta,Claudiu T. Supuran
DOI: https://doi.org/10.1002/ardp.202400626
2024-11-11
Archiv der Pharmazie
Abstract:The scientific literature dealing with the identification and development of selective inhibitors of the carbonic anhydrases expressed by the protozoans Trypanosoma cruzi (T. cruzi) and Leishmania spp. is reviewed and analyzed, with the aim to sustain the validation process of new classes of drugs useful for the management of neglected tropical diseases, that is, Chagas disease and leishmaniasis. Diseases caused by protozoan parasites represent a huge challenge to global health care, due to the lack of selective and efficient treatments for the management and spreading of such complex pathologies. The protozoans Trypanosoma cruzi (T. cruzi) and Leishmania spp. are the etiological agents of the so‐called neglected tropical diseases (NTDs), that is, Chagas disease (CD) and leishmaniasis, respectively. In such a context, the metalloenzymes carbonic anhydrases (CAs; EC 4.2.1.1) emerged as potential protozoan druggable enzymes, being involved in the parasites' life cycle. Several studies suggested the relevance of the protozoan‐expressed CAs as future candidates for the management of NTDs.
pharmacology & pharmacy,chemistry, medicinal, multidisciplinary
What problem does this paper attempt to address?